A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study

被引：0
|
作者：
Pimenta, Eduardo
Jensen, Markus
Jung, David
Lobmeyer, Maximilian
Schmitt, Walter
Schaumann, Frank
Boxnick, Stefanie
Truebel, Hubert
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
Heart failure; Vasopressins; Abdominal aortic aneurysm;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15196
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [2] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, M
    Thomas, I
    Ghali, JK
    Selaru, P
    Chanoine, F
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2001, 104 (20) : 2417 - 2423
  • [3] Renal effects of a novel dual acting V1a/V2 vasopressin receptor antagonist: comparison with furosemide
    Kolkhof, P.
    Stasch, J. P.
    Pook, E.
    Schmeck, C.
    Fuerstner, C.
    Albrecht-Kuepper, B.
    EUROPEAN HEART JOURNAL, 2011, 32 : 788 - 789
  • [4] Novel vasopressin V1A and V2 antagonist (Conivaptan) increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure
    Verbalis, JG
    Ghali, JK
    Gross, P
    Long, WA
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S120 - S120
  • [5] Conivaptan hydrochloride.: Treatment of heart failure, Treatment of hyponatremia, Vasopressin V1a/V2 antagonist.
    Norman, P
    Leeson, PA
    Rabasseda, X
    Castañer, J
    Castañer, RM
    DRUGS OF THE FUTURE, 2000, 25 (11) : 1121 - 1130
  • [6] Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?
    Mondritzki, T.
    Pook, E.
    Wasnaire, P.
    Schmeck, C.
    Kolkhof, P.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1317 - 1317
  • [7] Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist
    Gunnet, Joseph W.
    Wines, Pamela
    Xiang, Min
    Rybczynski, Philip
    Andrade-Gordon, Patricia
    de Garavilla, Lawrence
    Parry, Tom J.
    Cheung, Wai-man
    Minor, Lisa
    Demarest, Keith T.
    Maryanoff, Bruce E.
    Damiano, Bruce P.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) : 333 - 342
  • [8] Pharmacotherapy for hyponatremia in heart failure:: Effects of a new dual V1A/V2 vasopressin antagonist YM087
    Abraham, WT
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    McCord, J
    Rydzinski, S
    Nelson, CB
    Bakker-Arkema, RG
    CIRCULATION, 1999, 100 (18) : 299 - 299
  • [9] Conivaptan:: A dual vasopressin receptor V1a/V2 antagonist (vol 25, pg 261, 2007)
    不详
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (04): : 397 - 397
  • [10] LIXIVAPTAN Vasopressin V2 Receptor Antagonist Treatment of Heart Failure Treatment of Hyponatremia
    Daifallah, S.
    Zmily, H. D.
    Alqwasmi, A. H.
    Zayed, H.
    Ghali, J. K.
    DRUGS OF THE FUTURE, 2011, 36 (05) : 359 - 370
12345